力世紀(00860.HK)折讓19.3%配股淨籌近4.9億元 下午復牌
力世紀(00860.HK)公布,公司今日(7日)與不少於六名認購方訂立協議,以每股0.46元向認購方配發共10.67億股新股,較股份上交易日(4日)收市價每股0.57元折讓約19.3%。配發數目相當於公司已發行股份總數約14.88%;及經擴大總數約12.95%。
是次配發所得款項淨額預計約為4.86億元,約90%將用於未來潛在收購或投資新能源汽車相關業務或技術;及約10%將用作一般營運資金。
應公司要求,股份已於今日上午在聯交所短暫停止買賣。公司已向聯交所申請自今日下午1時正起恢復股份買賣。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.